Avantium Provides Crystal16™ to all Research Sites of Sanofi-Aventis

Avantium Technologies has announced an agreement with Sanofi-Aventis for the deployment of its proprietary Crystal16™ at all research & development centers of Sanofi-Aventis. 

Sanofi-Aventis has selected the Crystal16™ for the enhancement of its crystallization research capabilities, to increase the experimental throughput of its scientists and to be able to perform crystallization experiments on a smaller scale.

"We are pleased to provide our Crystal16™ platform to the global Sanofi-Aventis research organization," commented Guus Scheefhals, Chief Business Officer at Avantium.

"This agreement validates Avantium's strategy to provide high-value added tools next to its services business."

The Crystal16™ is a platform for performing parallel crystallization experiments in 1-ml reactors.

The Crystal16™ is designed to be used for a range of applications in pharmaceutical and chemical research, such as solubility measurements, improving the understanding of crystallization processes and the generation of crystals for product characterization.